Control of the immune response by pro-angiogenic factors - sprookjes - yvandenbroek - TriplyDB

Control of the immune response by pro-angiogenic factors

Control of the immune response by pro-angiogenic factors

http://www.wikidata.org/entity/Q27004733

about

Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate Targeting the tumor vasculature to enhance T cell activity Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours Anti-CD27 Antibody Potentiates Antitumor Effect of Dendritic Cell-Based Vaccine in Prostate Cancer-Bearing Mice.Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.Human Mesenchymal Stromal Cells Transplantation May Enhance or Inhibit 4T1 Murine Breast Adenocarcinoma through Different Approaches Cell type- and tumor zone-specific expression of pVEGFR-1 and its ligands influence colon cancer metastasis.Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer.Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients.Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer The recurrence pattern following delayed breast reconstruction after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases.Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer PD-1(+) and Foxp3(+) T cell reduction correlates with survival of HCC patients after sorafenib therapy Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis.Angiogenic factors and inflammation in steroid-refractory acute graft-vs-host disease.PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion Structural Determinant and Its Underlying Molecular Mechanism of STPC2 Related to Anti-Angiogenic Activity Immune Regulation by T Regulatory Cells in Hepatitis B Virus-Related Inflammation and Cancer.MicroRNA-34a promotes genomic instability by a broad suppression of genome maintenance mechanisms downstream of the oncogene KSHV-vGPCR.Immunotherapy of colorectal cancer: new perspectives after a long path.Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.Commentary: A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment.Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response.Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells.Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.Immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells.Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer.

P2860

Q26777205-D96464E1-BC39-423A-A2D0-D481FE9E6C0C Q27026329-9FC832AB-EAA8-4797-9338-7286F7574C0D Q28078539-ABBDA327-D50F-4FDB-A2B4-2616A325D0FC Q30275254-19ABBCD5-2AC4-4DDE-B1E9-29EC2BC2B7C1 Q33433105-C757BC9E-CE14-4704-A234-BD937E1AAB31 Q34993204-634C8402-ACB6-435B-B9FC-515FDBCB20A0 Q35506659-19DF1E73-9AFC-45C3-B06B-EE726F2F9AC4 Q35592434-D43D81EA-2645-4260-8C7F-4D346E2E4FD3 Q35603983-9BCC7173-12F1-4CF4-A7EA-EDE6A48594AC Q35627827-A13A4DE2-1D60-46E1-B497-BB2E1C3961F7 Q36420167-1FCCCBAD-7915-4D38-87E4-162E2E254178 Q36553576-CF192222-6C0C-49DB-B6B7-907673241002 Q36730827-B5247204-1A56-4909-BC6C-0F7EE752B664 Q36854062-14D67F7C-5C0D-41F0-8395-49CD4091D1E5 Q37024656-D5A47A75-566C-466D-B892-570254696065 Q37057942-2E22EC32-D430-416B-9FD9-BABCA79B113A Q37075642-9DF16F57-CA21-4152-A31A-60D5272C9A36 Q37079133-C067A46A-0CE6-40E2-A0CE-884E48C1AE1A Q37179971-ED548732-B5C5-4077-8D6B-8C84BF9DE8BF Q37237228-803A7273-A37E-4F78-BF75-7B4B838367A1 Q37678218-25996F09-CE07-4BF9-AF0F-B66A85B63D85 Q38539063-F901EBEF-C519-4BC7-9F13-CA3A1FD2E588 Q38649562-F3A66C98-362A-4AD6-97A9-37EFDEC06208 Q38706890-EBFD986C-FF13-4D76-BA5F-8028AF8C9389 Q38715245-A0D3F2CD-9CD8-44E8-9CA2-E46A11FB655B Q38767613-9DF6D78A-2EE1-4C05-822C-F13B66804BD1 Q38794695-F16F7ABF-B5CA-4DD1-91FE-AA68845D6FFB Q39043413-810651B9-D880-4AFB-BC8D-AED7EF0522E1 Q40535967-F05AE13A-0E4E-41B6-AA3E-19FE80465058 Q40979902-BAFDEF15-F478-4B22-A974-14D02F29B9AE Q40985733-AC88D554-9AB9-4284-94D6-17144CCE590E Q41147045-FCCEF8CD-70CD-457A-A82A-F6C45654CEFF Q41588307-DBEA737A-59A2-49E0-970F-2A1C3391115F Q41813115-D65A7A60-A5A9-4E52-B453-0B48EA2BFAD6 Q47104348-0EC1FEF9-F09A-422A-A029-3412BE8AB93B Q47114407-E82C7ECC-1ACD-483D-BBFD-E75204418E4A Q47350013-3FBBC317-F06F-4861-B894-CFB3B465B40E Q49382862-2CAF5E99-F42D-4147-8C83-CACA319A9FAB Q50019794-8DB47F1D-5AA3-44BF-A05E-FB759387A719 Q50550722-0A9B06B2-B9D0-49A1-87D7-FCC0734F9D61

P2860

Control of the immune response by pro-angiogenic factors

http://www.wikidata.org/entity/Q27004733

description

2014 nî lūn-bûn

@nan

2014 թուականին հրատարակուած գիտական յօդուած

@hyw

2014 թվականին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Control of the immune response by pro-angiogenic factors

@ast

Control of the immune response by pro-angiogenic factors

@en

Control of the immune response by pro-angiogenic factors

@nl

type

label

Control of the immune response by pro-angiogenic factors

@ast

Control of the immune response by pro-angiogenic factors

@en

Control of the immune response by pro-angiogenic factors

@nl

prefLabel

Control of the immune response by pro-angiogenic factors

@ast

Control of the immune response by pro-angiogenic factors

@en

Control of the immune response by pro-angiogenic factors

@nl

P1433

Q27004733-1FA06A99-8B4F-43FB-B90C-FF7F238CFD28

P1476

Q27004733-6CBE7209-0A3F-4C67-9AC3-9ADCC0F4F84C

P2093

Q27004733-72A8E542-3774-4124-A192-EFE27DE830A1

Q27004733-74B18CBD-CD47-41DE-9BD0-1DE9DCFD4C90

Q27004733-E3CAA5C0-82E9-43DD-978E-348186163E5A

Q27004733-F5224124-3832-4EF1-8602-12346C418CD4

P2860

Q27004733-019EFAEB-3875-493E-9383-7BC2D4993330

Q27004733-041F2E64-A380-4CE0-AE70-DFE3F7A246B8

Q27004733-057FADA9-49D7-4E0E-A4C6-1A01A7F70E07

Q27004733-0784F853-C1EF-4119-8537-EC1842F7649E

Q27004733-0BCF8843-20F5-49C8-9B5F-B1D08942A4E7

Q27004733-0C168857-076D-4EBB-8030-CEEFA0B6DDE1

Q27004733-0E5A96A9-E2B6-43D0-BA1A-4633FFB86C22

Q27004733-12DCFEE4-A923-4C19-9C97-51E3B2022241

Q27004733-15AC290A-6C96-4160-AF6B-802595F26335

Q27004733-17BB42D7-44FE-402C-9FCB-B98FDCFDF151

P304

Q27004733-E13AB9BC-7723-4DB6-A32E-F72E8A272407

P31

Q27004733-D4E385A5-4AB6-41A5-AEFA-D9F3BD5702D4

P3181

Q27004733-A2D8BE92-B74F-419A-9184-5AE3E3C0EDC2

P356

Q27004733-7C5A0A90-75F3-4BB5-8B6D-CE2471AA022D

P407

Q27004733-10095EBE-5CD3-4786-8D76-7FBFFF9D4525

P478

Q27004733-52537751-E114-48E9-AD23-9337F62D51B7

P50

Q27004733-586C1246-430A-47BD-9179-4A4421F791A7

Q27004733-656F5977-5297-4404-894A-09F81C2A0CCB

Q27004733-6F8E63EE-5382-4116-A7F4-952483929527

P577

Q27004733-E6AC006F-65F3-44D1-873A-C229FBAFFAC1

P5875

Q27004733-DB4F4478-162A-45AC-B9C9-92C6D8F3411C

P698

Q27004733-1DC0CD02-3166-4241-8268-D791D4E27580

P932

Q27004733-4C4B777E-CDF0-4B44-BC81-B7ED7EAD7DE3

P3181

P356

FONC.2014.00070

P1433

Frontiers in Oncology

P1476

Control of the immune response by pro-angiogenic factors

@en

P2093

Elie Marcheteau

http://www.w3.org/2001/XMLSchema#string

Orianne Colussi

http://www.w3.org/2001/XMLSchema#string

Simon Pernot

http://www.w3.org/2001/XMLSchema#string

Thibault Voron

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Hallmarks of Cancer: The Next Generation

HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis

Cancer; a biological approach. I. The processes of control

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Dendritic cells and the control of immunity

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

P304

70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

608872

http://www.w3.org/2001/XMLSchema#string

P356

10.3389/FONC.2014.00070

http://www.w3.org/2001/XMLSchema#string

P407

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261884234

http://www.w3.org/2001/XMLSchema#string

P698

24765614

http://www.w3.org/2001/XMLSchema#string

P932

3980099

http://www.w3.org/2001/XMLSchema#string